The biopharma industry outlook on 2024: Guarded optimism for a rebound
Guarded optimism seems to be the mood of the biopharmaceutical industry to start 2024.
Last year brought a stock market slide and layoffs for more than 150 drug companies. Financial and regulatory headwinds, like the March collapse of Silicon Valley Bank and a more strident Federal Trade Commission, further weighed on the sector.
There are now some signs of a turnaround, from a rebounding market to a flurry of pharma company acquisitions. Surging demand for new obesity drugs has lifted Eli Lilly and Novo Nordisk, while catalyzing an industry-wide race to follow them. The Food and Drug Administration may soon approve a new Alzheimer’s drug. Antibody-drug conjugates and radiopharmaceuticals promise to offer new ways of treating certain cancers.
Perhaps more importantly, the Federal Reserve has signaled plans to cut interest rates, potentially making a high-risk sector like biotech more appealing to investors.
Still, the effects of the downturn may not be so easy to shake off. Already more than half a dozen biotech companies have announced layoffs, and venture investors have signaled changes in how they plan to build new startups. Larger drugmakers still face sizable patent cliffs that they need to solve. And a U.S. presidential election could bring political scrutiny.
Read on for a look at what’s in store this year.
-
5 questions facing pharma in 2024
By Jonathan Gardner and Ned Pagliarulo • Jan. 10, 2024New drugs for obesity and cancer are the focus of many pharma companies, some of which are also grappling with how to manufacture complex cell and gene therapies. Read the full article ➔
-
5 questions facing emerging biotech in 2024
By Gwendolyn Wu • Jan. 8, 2024An unusual FTC challenge could have implications for startups, while industry watchers gauge whether the sector’s recent momentum will end a lengthy funding crunch. Read the full article ➔
-
Newly optimistic, biotech investors weigh lessons of sector’s downturn
By Ben Fidler • Jan. 11, 2024Investors and executives interviewed by BioPharma Dive at J.P. Morgan say new companies have to be leaner, hire more conservatively and focus on their first medicines quickly. Read the full article ➔
-
10 clinical trials to watch in the first half of 2024
By Ben Fidler, Jacob Bell, Ned Pagliarulo, Jonathan Gardner and Delilah Alvarado • Jan. 2, 2024A non-addictive pain pill faces its definitive test, while study results in ALS and for a Duchenne gene therapy could have far-reaching implications. Read the full article ➔
-
5 FDA decisions to watch in the first quarter
By Ben Fidler and Ned Pagliarulo • Jan. 4, 2024The agency could soon issue verdicts on new drugs from Eli Lilly and Merck, as well as on what could be the first TIL therapy. Read the full article ➔